Skip to main content

End Stage Renal Disease on Dialysis

Nephrology
1
Pipeline Programs
6
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
Boehringer Ingelheim·Peak8.6yr
#3TRULICITYStable
$7.4B
Eli Lilly and Company·Peak
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

Vertex Pharmaceuticals
41Growing
Outset Medical
21Growing
Calyxo
20Growing
Biogen
8Stable
AstraZeneca
5Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Sequana Medical
Sequana MedicalGermany - Munich
1 program
1
Interdialytic peritoneal ultrafiltration with 10% dextrose solutionPhase 21 trial
Active Trials
NCT04603014Active Not Recruiting10Est. Dec 2025
Outset Medical
Outset MedicalSAN JOSE, CA
1 program
Dialysate Flow RateN/A1 trial
Active Trials
NCT05947708Completed41Est. Jan 2020
Baxter
BaxterCosta Rica - Cartago
1 program
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRTN/A
Baxter International
1 program
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRTN/A1 trial
Active Trials
NCT04286477Unknown45Est. Dec 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
endoAVFN/A1 trial
Active Trials
NCT05654103Recruiting90Est. Jan 2028
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Empagliflozin 25 mg vs PlaceboPHASE_41 trial
Active Trials
NCT05671991Recruiting30Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boehringer IngelheimEmpagliflozin 25 mg vs Placebo
Sequana MedicalInterdialytic peritoneal ultrafiltration with 10% dextrose solution
Angeles TherapeuticsendoAVF
Outset MedicalDialysate Flow Rate
Baxter InternationalThe Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT

Clinical Trials (5)

Total enrollment: 216 patients across 5 trials

NCT05671991Boehringer IngelheimEmpagliflozin 25 mg vs Placebo

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Start: Mar 2023Est. completion: Jun 202630 patients
Phase 4Recruiting
NCT04603014Sequana MedicalInterdialytic peritoneal ultrafiltration with 10% dextrose solution

Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients

Start: Jan 2021Est. completion: Dec 202510 patients
Phase 2Active Not Recruiting
NCT05654103Angeles TherapeuticsendoAVF

Comparing Surgical and Endovascular Arteriovenous Fistula Creation

Start: Nov 2024Est. completion: Jan 202890 patients
N/ARecruiting
NCT05947708Outset MedicalDialysate Flow Rate

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

Start: Sep 2019Est. completion: Jan 202041 patients
N/ACompleted
NCT04286477Baxter InternationalThe Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT

The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT

Start: Nov 2018Est. completion: Dec 202245 patients
N/AUnknown

Related Jobs in Nephrology

Farm Operations Technician

eGenesiseGenesis
Greater Madison, WI Area
3d ago

Sr. Research and Development Technician - Pleasanton, CA

CalyxoCalyxo
Pleasanton, CA
4d ago
$85K - $96K/yr

Chicago South based Clinical Specialist - Remote, USA

CalyxoCalyxo
Remote
5d ago
$100K - $140K/yr

Platform Engineer

AxiomAxiom
SF Global HQ
5d ago

Wilmington, NC based Territory Sales Manager - Remote, USA

CalyxoCalyxo
Remote
6d ago
From $120K/yr

Statistical Programmer Contractor

ProKidneyProKidney
6d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 216 patients
6 companies competing in this space

Related Indications

Chronic Kidney Disease(220)End Stage Renal Disease(203)Renal Impairment(142)Kidney Transplantation(136)Chronic Kidney Diseases(71)Renal Insufficiency(66)Acute Kidney Injury(66)Kidney Diseases(46)Renal Transplantation(45)Kidney Transplant(41)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.